Articles tagged with Cancer
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
Researchers developed a new diagnostic chip that can detect tumor cells in blood, allowing for real-time monitoring of brain cancer treatment effectiveness. The GlioExoChip uses extracellular vesicles to assess treatment response, providing a quick and minimally invasive way to inform doctors about chemotherapy efficacy.
Researchers have developed a new strategy to target mRNA cancer vaccines by teaching the immune system to recognize and destroy tumors. The treatment uses chimeric nanobodies that bind to tumor surface proteins, releasing mRNA that stimulates an immune response against cancer cells.
Research from the UMBERTO Project found that adopting healthy lifestyles such as eating well, exercising regularly and maintaining a balanced weight significantly reduced cancer mortality. The study showed a strong link between traditional cardiovascular risk factors and survival in people with a history of cancer.
Researchers at the University of Houston have discovered a potential therapeutic strategy for counteracting muscle wasting in pancreatic cancer by blocking a specific cell pathway. Muscle wasting, also known as cachexia, is a debilitating syndrome affecting 60-85% of patients with pancreatic cancer.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Researchers found that alcohol causes DNA damage, which can lead to cancer, and discovered a repair mechanism using the SXE enzyme complex. Individuals with genetic mutations affecting DNA repair may be more susceptible to alcohol-related cancers.
Researchers discovered that a bacterium isolated from Japanese tree frogs has complete tumor-eliminating properties. The study found that this bacterium attacks cancer through two mechanisms, selectively accumulating in tumors and evading the immune system.
The BRIDGE Program provides coordinated support across disease types to address the rising issue of early-onset cancer, offering fertility counseling, genomic testing, and community education. The program also fuels research into tumor biology and outcomes for younger patients affected by cancer.
Researchers have created an mRNA system that activates therapeutic genes in specific cell populations, potentially leading to safer and more precise cancer treatments. The system uses microRNAs to recognize cancer cells and shuts off the treatment if it's not needed, reducing toxicity and expanding mRNA therapy's reach.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Maher El-Kady's work on sustainable energy storage technologies aims to create a cleaner, more accessible future. Dr. Dennis Slamon's breakthroughs in breast cancer treatment have benefited millions worldwide, highlighting the impact of UCLA researchers on global health and innovation.
Researchers have made significant progress in treating non-small cell lung cancer (NSCLC) with targeted therapies, including tyrosine kinase inhibitors (TKIs) that target specific gene mutations. These treatments have shown effectiveness across various patient groups and improved outcomes for those with actionable mutations.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
Chromatin accessibility maps reveal that MDS stem cells gradually lose their normal identity and acquire characteristics typical of myeloid progenitors. A 'progenitor score' developed by the team tracks cell movement toward a progenitor-like state, correlating with disease severity and prognosis.
A global study found that patients with mature nodal T-cell lymphoma who relapsed within 12 months of initial treatment had worse survival outcomes, but improved survival when treated with targeted therapies instead of chemotherapy. The results suggest the need for personalized treatment strategies for high-risk patients.
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
CEMIP is associated with the breakdown of myelin, a protective sheath around nerve cells. Elevated levels of the enzyme inhibit myelin regeneration in people with multiple sclerosis. Researchers hope targeting CEMIP may promote central nervous system repair and slow disease progression.
MIT researchers have found a new way to create solid particles of highly concentrated antibodies, suspended in a solution, which can be injected using a standard syringe. This advance could make antibody treatments more convenient and accessible for patients, particularly older people with difficulty visiting hospitals.
The grant aims to increase individual screenings and change how health systems embed evidence-based screening practices into everyday operations. PA-CARES will work with trusted organizations in 28 counties with the lowest screening rates to implement effective screening options and facilitate timely linkage to care.
Researchers have identified the enzyme N4BP2 as the key driver of chromothripsis, a process in which cancer cells rapidly evolve and become resistant to treatment. The study reveals that tumors with high N4BP2 expression exhibit significantly more chromothripsis and structural rearrangements.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
Researchers used CRISPR technologies to discover previously unannotated DNA stretches in the 'dark genome', which control cell response to mechanical properties of their environment. This work could lead to new therapeutic targets for illnesses involving changes to tissue mechanics, including fibrosis and cancer.
A Stanford Medicine-led study reveals that a signaling pathway controls the immune response, allowing researchers to potentially treat various diseases. The research focuses on peripheral immune tolerance, which prevents inappropriate attacks on healthy tissue.
A case report describes a woman with radiation-induced cellular changes in her Pap smear that mimicked cancer recurrence. The study emphasizes the importance of recognizing these changes to prevent misdiagnosis and unnecessary medical procedures.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
A NIH-led study identified key factors driving tumor evolution and influence outcomes in lung cancer, revealing a previously unknown origin of aggressive tumors associated with the ID2 mutational signature linked to LINE-1 reactivation. Major driver gene mutations also influenced tumor evolutionary trajectories.
Researchers at OIST have discovered that certain cancers can 'lose their sense of time' to avoid cellular stress responses. The study highlights the role of USP28 in stabilizing p53, a known tumor suppressor, and how mutations in this protein can disrupt its function.
Veterans and first responders face elevated risk of cancer due to occupational exposures, such as firefighting. Experts call for better access to high-quality cancer prevention, screening, and treatment, including presumptive laws and expanded support services.
A cohort study found that older Medicare beneficiaries with common metastatic cancers had a mean of 40 to 62 health care contact days after diagnosis. Health care contact days increased from 2008 to 2019, highlighting the need for oncology teams to discuss expected burdens when developing care goals and treatment plans.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
The MUTE-Seq method detects rare cancer mutations at exceptionally low frequencies, enriching circulating tumor DNA and improving detection accuracy. It increases variant allele frequencies by tens of times, enabling detection of mutations present at 0.005% or lower.
Researchers have developed an AI-driven method to uncover genetic interactions driving cancer progression. The approach highlights complex interplay between genes allowing malignant cells to gain momentum and reveals previously hidden cancer drivers.
A study by Van Andel Institute scientists found that reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively. The researchers discovered that a low-fat, high-protein diet given once a day promotes the formation of ketones, which act as a cellular fuel for T cells to become more effective tumor fighters.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
Researchers have discovered triaptosis, a novel cell death mechanism that selectively targets and kills cancer cells, offering a new hope in oncology. This process is mechanistically distinct from all previously known cell death pathways and holds considerable promise for combination with immunotherapy.
Researchers present promising new data from two ongoing studies of pivekimab sunirine targeting CD123 in treating two aggressive blood cancers, acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The triplet regimen including pivekimab sunirine showed high response rates and enabled stem cell transpla...
A study finds that most people trust doctors more than AI for health diagnoses, but have a positive view of AI's potential in cancer diagnosis. The research used two nationally representative surveys to assess public attitudes toward AI in healthcare, including trust, understanding, and excitement.
A new study identifies a practical and powerful prognostic marker that can help clinicians tailor treatment strategies to improve survival for patients with aggressive T-cell lymphoma. Researchers found that patients who relapse within 12 months of initial therapy have a dramatically declining chance of survival, making targeted therap...
Researchers discover that CDT1 overexpression suppresses DNA replication and induces DNA damage, potentially leading to genetic mutations and cancer. The study provides molecular insights into the role of CDT1 in cancer development.
Patients with lower-risk myelodysplastic syndromes experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations. The five-day regimen offered the best balance of safety and efficacy, demonstrating improved event-free survival and overall survival.
A new computational tool has discovered a previously unknown protein pathway that triggers the death of blood cancer cells when blocked. This finding could lead to new treatments and improved survival rates for patients with aggressive acute myeloid leukaemia (AML).
Researchers developed an antibody therapy called 77A that targets HSP70, a heat shock protein helping tumors evade the immune system. The treatment showed strong antitumor effects by enhancing immune cell activity in laboratory models of multiple cancer types.
Researchers mapped NBCn1's structure-function properties to understand how breast cancer cells thrive in hostile environments. The study provides insights into the protein's dynamics and ion transport pathways, paving the way for designing drugs that target this transporter.
Researchers have developed a simple urine test that can effectively diagnose and stage bladder cancer using cell-free DNA fragmentation analysis. The study found that specific patterns of cfDNA fragmentation can identify muscle-invasive bladder cancer with excellent specificity and predictive value.
Researchers at UCLA present several new studies on emerging blood-based surveillance tools, new approaches to predicting treatment response, and tailoring therapies across the disease spectrum for patients with breast cancer. The findings highlight the potential of precision medicine in improving quality of life.
The ACRF MATRIX Centre will enable researchers to study cancer cells and their surrounding environment with unprecedented molecular resolution. This will help develop combination therapies targeting both cancer cells and the microenvironment.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
A new remote group intervention, CRAFT-G, combining cognitive training and occupational-therapy-based strategies, showed high satisfaction and clinically meaningful improvements in daily functioning among cancer survivors. The program proved to be accessible and effective in helping survivors manage 'chemobrain' and reclaim everyday life.
A survey study found that overall trust in scientists as sources of cancer information is high, but ideologically diverse. The results suggest the need for tailored messaging and trusted messengers to reach diverse audiences with evidence-based cancer information.
A new organ-on-a-chip platform recapitulates age-dependent immune responses, allowing for more accurate testing of cancer vaccines in older adults. The platform reveals functional differences in immune responses between young and old lymphocytes, which are not detectable with traditional 2D cultures.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
MIT chemists successfully synthesized verticillin A, a fungal compound that has shown potential as an anticancer agent. The researchers then generated derivatives of the compound and tested them against pediatric brain tumors, finding that some were effective against cancer cells with high levels of EZHIP protein.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers found that sudden cardiac death (SCD) among colorectal cancer patients decreased overall, but disparities remained based on age, sex, and geographic location. The study highlights the need for tailored heart monitoring and care strategies for cancer patients, particularly in underserved groups.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
A recent study by UCLA Health investigators found that mental health conditions significantly raise the likelihood of developing liver cancer among US veterans living with cirrhosis and hepatitis C. The study suggests that these disorders limit access to hepatitis C care, reducing the chance of a cure.